Press Releases

Report Date Files
Portage's Biohaven Orphan Drug Designation Request Granted for the Treatment of Spinocerebellar Ataxia 03 March 2016 Click to open
Portage's Biohaven Announces Expedited Development Path for BHV-0223 Following Successful Pre-IND Interaction with FDA 25 February 2016 Click to open
Portage's Biohaven Announces Positive Results from Phase I Study with BHV-0223 24 February 2016 Click to open
Mr. James Mellon and Dr. Gregory Bailey ("Offerors") Announce Additional Shares in Portage Biotech Inc. 14 December 2015 Click to open
Portage's Biohaven Announce Phase I Pharmacokinetic Study Meets Study Objectives and Supports Advancing BHV-0223 and also Appoints a CEO 19 November 2015 Click to open
Portage's Biohaven Completes Multiple Dose Phase of Pharmacokinetic Trial with BHV-0223 06 October 2015 Click to open
Biohaven and Fox Chase Chemical Diversity Center Announce Strategic Alliance in Early Stage Drug Discovery Research 01 October 2015 Click to open
Portage's Biohaven Completes Single Dose Phase of Pharmacokinetic Trial with BHV-0223 21 September 2015 Click to open
Portage's PPL Will Advance its Lead Candidate PPL-003 to an IND for Dry Eye Disease and Uveitis 31 August 2015 Click to open
Portage's Biohaven Doses First Human Subject in Phase I Trial with Lead Drug Candidate BHV-0223 27 August 2015 Click to open
Portage's Biohaven Acquires Intellectual Property for Portfolio of Prodrugs from ALS Biopharma, LLC 18 August 2015 Click to open
Portage's Biohaven Raises US$4.1 Million in First Tranche of Private Placement. Portage Invests $2.5M 11 August 2015 Click to open
Portage Invests in Sentien Biotechnologies, Inc. 10 August 2015 Click to open
Portage's Biohaven Announces IND Filing for BHV-0223 for Phase I Clinical Testing 23 July 2015 Click to open
Portage Completes Non-Brokered Private Placement in Two Tranches for Total Proceeds of US$ 5,155,080 25 June 2015 Click to open